Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Background Real‐life data on newer biological and biosimilar agents for moderate‐to‐
severe psoriasis are lacking. Objectives To examine safety, efficacy and time to …

In a non‐life‐threatening disease such as psoriasis, treatment goals should be referred to
the improvement in severity and extent of the disease and their impact on patients' perceived …

Objectives We aimed to (1) identify and classify spin (ie, a description that overstates efficacy
and/or understates harm) in systematic reviews and (2) rank spin in abstracts of systematic …

Objective: To systematically analyze the efficacy and safety of interleukin (IL)-12/23, IL-17,
and selective IL-23 inhibitors in moderate to severe plaque psoriasis. Methods and results …

Psoriasis is a complex chronic inflammatory cutaneous disorder. To date, robust molecular
mechanisms of psoriasis have been reported. Among diverse aberrant immunopathogenetic …

Psoriasis is a chronic inflammatory skin disorder effectively treated by blocking IL-17RA, a
receptor chain used by several IL-17 family members, including IL-17E. Although IL-17A is …

Background Drug survival is a marker for treatment success. To date, no analyses relating
dermatological quality‐of‐life measures to drug survival have been published. Objectives (i) …

The expression of genes encoding for Th1, Th2 and Th17 cytokines has been extensively
evaluated in differentiated skin cells of psoriatic patients. The microenvironment exerts a …